Janssen gets priority review for prostate cancer combo; ImmunoGen reports Q1 Elahere sales
Janssen’s combination therapy of niraparib with abiraterone acetate plus prednisone for the treatment of BCRA-positive metastatic castration-resistant prostate cancer (mCRPC) is moving along.
Jannsen posted on Twitter on Friday morning that its submission to the FDA for the combination therapy has received a priority review. The drug combo was submitted for an NDA back in March.
UPDATE: Our submission to the U.S. FDA for a new targeted therapy for patients with BRCA-positive metastatic castration-resistant #ProstateCancer #mCRPC has received Priority Review. https://t.co/56gMkdGWQI https://t.co/UUmAs7ChdI
— Janssen Global (@JanssenGlobal) April 28, 2023
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.